tional. In 2013 we described the first case of anaphylaxis due to Messor barbarus (MB) ant in a patient with hymenoptera venom allergy and systemic mastocytosis (SM). SDS-PAGE Immunoblotting identified an IgE binding band of 45-55 kDa in the extract of MB's body which showed partial cross-reactivity with venom protein from Apis, Polistes and especially Vespula. Thus, we decided to investigate the possible sensitization to MB proteins in a sample of patients with Hymenoptera venom hypersensitivity. METHODS: Twenty-two patients were studied. Exhaustive anamnesis of exposition and reaction to ant bites, prick test with MB's body extract (10 mg/ml), tryptase serum determination, and REMA score (Spanish Network on Mastocytosis) to predict systemic mastocytosis were carried out. RESULTS: Three women and 19 men, average age of 50 years, were studied. Sixteen presented with systemic reactions and 6 local ones. Four of 22 patients referred ant bites but only one experienced symptoms (anaphylaxis). Prick tests with MB's body extract were positive in 10 patients. Only in 3 patients, subsequently diagnosed of systemic mastocytosis, tryptase serum was positive and REMA score was more than 2 points. CONCLUSIONS: We detected sensitizations to MB ant body in almost half of patients with Hymenoptera venom hypersensitivity. Nevertheless, we do not know its clinical relevance because most of them had not suffered ant bites. But taking into account our previously reported case, we consider that the investigation of sensitization to other kinds of Hymenoptera may be of interest, especially in patients with systemic mastocytosis. Hungarian Angioedema Reference Center, Third Department of Internal Medicine, Semmelweis University, Budapest, Hungary. RATIONALE: In a phase 2 trial, BCX7353 was superior to placebo in reducing the angioedema attack rate (N Engl J Med 379: 352-362, 2018) . We hypothesized that BCX7353 would also be superior to placebo in treating angioedema attacks. METHODS: ZENITH-1 is a double-blind, placebo-controlled, randomized, cross-over, dose-ranging trial. Adults with HAE Type I or II selfadministered a dose of blinded study drug for 3 attacks: 2 treated with active drug and 1 with placebo, in a randomized sequence. Subjects were free to use approved on-demand medications if needed, but were asked to wait 4h post-study drug if possible. Symptom diaries were completed prior to dosing and at 1, 2, 3, 4, 8 and 24h after study drug. Outcomes were compared using generalized logistic regression models. The completed first dose cohort (750mg) is reported; lower dose cohorts (500mg or 250mg) are in progress. RESULTS: 33 patients treated a total of 95 attacks; 30 treated all 3 attacks. At 4h postdose, 67.7% of BCX7353-treated angioedema attacks versus 46.7% for placebo were stable or improved by composite VAS (OR52.771, p50.0387). At 24h, subjects reported no or mild symptoms by patient global assessment in 64.1% of BCX7353-treated attacks versus 32.3% for placebo (OR54.614, p50.0038). Rescue medication was used in 29.7% of attacks treated with BCX7353 compared with 61.3% of placebo attacks (OR50.196, p50.0029). There were no Grade 3/4 AEs or laboratory abnormalities. CONCLUSIONS: BCX7353 750mg was superior to placebo and was well-tolerated. These results support further development of BCX7353 as an oral on-demand treatment for HAE attacks.
